The response rate of 57% in lung adenocarcinomas with ALK rearrangements and the progression‐free survival of treated patient was in excess of 6 months, and led to the FDA approval of crizotinib for ALK rearranged tumors in 2011.48 There are now five different FDA approved drugs, crizotinib, ceretinib, alectinib, brigatinib, and lorlatinib, for ALK‐rearranged tumors and the median progression‐free survival is nearly 3 years. The gene discussed is ALK; the disease is lung adenocarcinoma.